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Abstract
Background: During the extremely challenging 4,487 km ultramarathon TransEurope-FootRace 2009, runners
showed considerable reduction of body weight. The effects of this endurance run on brain volume changes but
also possible formation of brain edema or new lesions were explored by repeated magnetic resonance imaging
(MRI) studies.
Methods: A total of 15 runners signed an informed consent to participate in this study of planned brain scans
before, twice during, and about 8 months after the race. Because of dropouts, global gray matter volume analysis
could only be performed in ten runners covering three timepoints, and in seven runners who also had a follow-up
scan. Scanning was performed on three identical 1.5 T Siemens MAGNETOM Avanto scanners, two of them located
at our university. The third MRI scanner with identical sequence parameters was a mobile MRI unit escorting the
runners. Volumetric 3D datasets were acquired using a magnetization prepared rapid acquisition gradient echo
(MPRAGE) sequence. Additionally, diffusion-weighted (DWI) and fluid attenuated inversion recovery (FLAIR) imaging
was performed.
Results: Average global gray matter volume as well as body weight significantly decreased by 6% during the race.
After 8 months, gray matter volume returned to baseline as well as body weight. No new brain lesions were
detected by DWI or FLAIR imaging.
Conclusions: Physiological brain volume reduction during aging is less than 0.2% per year. Therefore a volume
reduction of about 6% during the 2 months of extreme running appears to be substantial. The reconstitution in
global volume measures after 8 months shows the process to be reversible. As possible mechanisms we discuss
loss of protein, hypercortisolism and hyponatremia to account for both substantiality and reversibility of gray
matter volume reductions. Reversible brain volume reduction during an ultramarathon suggests that extreme
running might serve as a model to investigate possible mechanisms of transient brain volume changes. However,
despite massive metabolic load, we found no new lesions in trained athletes participating in a multistage
ultramarathon.
See related commentary http://www.biomedcentral.com/1741-7015/10/171
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Background
In 2009 (19 April to 21 June) the TransEurope-FootRace
2009 (TEFR09) took place. It was the second European
transcontinental multistage ultramarathon race and cov-
ered the distance from the south of Italy (Bari) to the
North Cape [1,2]. A group of 67 endurance athletes with a
mean age of 50.7 years ranging from 26 to 74 and encom-
passing 11 women and 56 men from 12 nations met the
challenge. Their goal was to run 4,487 km (2,788 miles) in
64 days without a rest day. Therefore, they planned to
complete an average distance of 70.1 km daily, that is, 1.7
marathon distances per day (minimum: 44 km/day, maxi-
mum: 95.1 km/day) for 64 consecutive days [1].
Brain lesions due to marathon running can be caused by
many reasons. Some possible etiologies are facts, some are
hypotheses derived from specific observations: exercise-
associated hyponatremia in marathon runners is well
known [3-5] and has been observed in a substantial frac-
tion of long distance runners [6] and may lead to acute
encephalopathy and brain edema [7]. Hyponatremia possi-
bly arises from sodium loss caused by sweat and excessive
drinking, inadequate suppression of antidiuretic hormone
and inadequate mobilization of sodium from internal
stores [5], sequestration of water during the run and sud-
den inflow of water after cessation of the run. This process
can be accentuated by the widespread use of non-steroidal
anti-inflammatory drugs among long distance runners [8].
Fatal cases of brain edema after a marathon run have been
reported [6,7]. Edema in high altitude sickness has recently
been reattributed to free radicals rather than hypoxic dis-
ruption of the brain barrier [9], so this form of edema
might also arise in exhausting exercise in normal altitudes.
Exertion can also lead to arterial hypertension, which has
been linked to reversible posterior brain edema [10-12].
Disturbances of intravascular coagulation known to
happen in marathon runners [13,14] may induce cerebral
embolism. Also, brain lesions caused by prolonged asys-
toles due to ‘athlete’s heart’ have been described [15].
Magnetic resonance imaging (MRI) is the most appro-
priate method for brain imaging. White matter changes
detected by MRI are thought to be clinically relevant [16].
While visual rating scales have been widely used, lesion
volume is thought to be more sensitive [17].
In contrast to brain lesions, brain atrophy is a normal
physiological process, occurring mainly in the gray matter
(GM) with rates from 0.11% [18] to 0.18% per year [19].
Brain atrophy is accelerated up to 2% per year in patients
with Alzheimer’s disease [20,21]. Also, brain atrophy is
increased in patients with multiple sclerosis [22] or Hun-
tington’s disease [23], in which illness-related processes
may cause brain atrophy. Patients with malnutrition syn-
dromes such as anorexia nervosa [24], kwashiorkor [25] or
alcoholism [26] have been shown to exhibit brain volume
reduction, which is reversible by therapy [25-29]. The
exact mechanism for the observed brain volume reduction
is still not fully understood [24,25,28,30,31].
For exercise, no reports on accelerated brain atrophy
exist. So far, moderate exercise has been reported to
even prevent cognitive decline [32].
As expected from previous experiences from ultraendur-
ance events [33-35] showing massive energy deficits with
loss of fat and muscle mass, our TEFR09 participants also
showed signs of a strong catabolic burden indicated by a
considerable reduction of body weight (Figure 1).
Therefore, using repeated MRI measurements we investi-
gated changes in global gray matter volumes, which were
expected due to metabolic changes such as the energy defi-
cit associated with long distance running. Furthermore,
based on previous reports we performed lesion detection
MRI to investigate the athletes’ brains for edema or lesions.
Methods
Subjects
After approval of the local ethics committee (University of
Ulm, decision 78/08-UBB/se) and in accordance with the
Declaration of Helsinki, athletes without any contraindica-
tions to MRI were recruited after signing an informed
consent. A total of 15 participants were initially enrolled
into this natural study. We had planned to scan their
brains before, twice during, and 8 months after the race.
Due to the strong challenge and ensuing phenomena of
fatigue, the compliance of runners to participate in MRI in
the evening after a day of running was reduced and
resulted in dropouts, such that the data of only a reduced
number of runners could be included into the analysis.
We carried out a global volumetric analysis with ten ath-
letes covering three timepoints, and a second analysis with
seven runners who also had the follow-up at timepoint 4,
that is, 8 months after the end of the race.
All members of the ten-subject group (see Table 1) were
men, with a mean age of 48.8 years (SD 12.7). Body weight
was taken (always measured in the morning before break-
fast) with a Tanita BC-545 BIA scale (Arlington Heights,
IL, USA) to the nearest 0.1 kg. At the beginning of the
race, their mean body weight was 73.6 kg (SD 6.6). Train-
ing data were collected with a custom-made questionnaire
asking for training distances and times, races completed
and results from these races. In the year preceding the
race the ten runners had a mean training distance of 6,142
km (SD 2,367 km). Per week they performed a mean train-
ing distance of 118.3 km (SD 45.0 km) with a mean train-
ing duration of 12.9 hours/week (SD 3.4 h) and a mean
training velocity of 8.8 km/h (SD 1.5 km/h).
The dropout of three runners from this group who
were not able to participate in the follow-up did not sub-
stantially change the distribution of the above-mentioned
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variables (see Table 1). Mean age, body weight and train-
ing parameters in the year before the race did not differ
significantly.
As will be shown in the results section, both groups
were representative for the majority of runners who were
willing to provide these biological data.
MRI acquisition protocol
Scanning was performed on three identical 1.5 T Siemens
(Erlangen, Germany) MAGNETOM Avanto MRI scan-
ners with identical sequence parameters. Two scanners
were located at our university. The third was a mobile
MRI unit mounted on a truck escorting the runners [2].
The sequence parameters are given in Table 2, resulting
in an isotropic resolution of 1 × 1 × 1 mm for the volu-
metric data.
Scanning was performed in the afternoon or evening
after the completion of the daily stage, because the time
schedules of the athletes would not permit other times
(start in the early morning and running for 6 to 10 h).
During this running time the scanner was moved to a new
position at the new night quarters.
Study design
The first examination (timepoint 1) took place before the
start of the race. Timepoints 2 and 3 were examined at
2,400 km and 4,000 km and the follow-up was performed
at an average of 8 months after the end of race.
Figure 1 Mean body weight of the participating group of TransEurope-FootRace 2009 (TEFR09) athletes. Error bars denote standard
deviation; asterisks show statistically significant differences from baseline (timepoint 1).







P value of difference
(10 vs 34)
P value of difference
(7 vs 34)
Age in years 51.1 (11.5) 48.8 (12.7) 50.4 (10.2) 0.693 0.867
Height, m 1.78 (0.04) 1.79 (0.04) 1.74 (0.08) 0.072 0.202
Weight at start, kg 75.1 (6.8) 73.6 (6.6) 69.9 (10.0) 0.285 0.196
Pre-race training, km/year 6,513 (2,689) 6,142 (2,367) 5,355 (1,620) 0.230 0.132
Pre-race training, km/week 125.8 (51.5) 118.3 (45.0) 103.0 (30.4) 0.214 0.117
Pre-race training, h/week 13.5 (3.8) 12.9 (3.4) 12.6 (3.2) 0.771 0.491
Pre-race mean velocity, km/h 8.8 (1.3) 8.8 (1.5) 8.2 (1.4) 0.207 0.266
Values are given as mean (SD).
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Image interpretation of the diffusion-weighted imaging
(DWI) and fluid-attenuated inversion recovery (FLAIR)
images
Two readers (experienced radiologists WF and UHS)
independently interpreted the scans. To facilitate com-
parison between the scans, the images were read chron-
ologically and new or old lesions were differentiated.
The DWI echoplanar imaging (EPI) sequence was read
in the b1,000 weighting to search for focal or more diffuse
diffusion restriction as a sign of intracellular edema. The
FLAIR sequence was read to search for focal or diffuse sig-
nal alteration as a sign of edema or lesion.
The lesion volume of the three largest lesions was esti-
mated by multiplication of the perpendicular diameters.
If the lesion was only visible on one slice, the diameter
perpendicular to the slice orientation was estimated by
the mean of the two other diameters.
Statistical analysis of DWI and FLAIR image interpretation
Means and standard deviations and t tests (paired for
the comparison of timepoints) were calculated using MS
excel functions (Microsoft Office Excel 2003; Microsoft
Corporation, Redmond, WA, USA). Results with P <0.05
were considered as significant. Correlation tests were
computed to look for significant correlation of the num-
ber of lesions and biometrical (weight, height or age) or
sports-associated parameters (training intensity or parti-
cipation in ultramarathons).
Inter-rater reliability
For rating of the number of lesions in DWI and FLAIR,
the inter-rater reliability was analyzed.
Taking into account the critique of Bland and Altman
[36] concerning the correlation coefficients to calculate
the inter-rater reliability, we decided to use the parameter
lambda as proposed by Jepsen et al. [37]. Lambda can be
calculated as follows:
λ =
2 · VARX − VARD
2 · VARX
Where VAR denotes the variance of the measurements
X and D the difference between measurements of the
two raters. The inter-rater reliability is rated as low for
l <0.25. Values up to 0.5 are rated as fair, 0.5 to 0.75 as
moderate to good and l >0.75 demonstrates good to
excellent inter-rater reliability [38].
Data analysis of volumetric data from the magnetization
prepared rapid acquisition gradient echo (MPRAGE)
images
Analysis was performed with the software package SPM8
[39] including the VBM8 toolbox [40]. Preprocessing of
imaging data before the statistical analysis was carried
out using a specific batch for longitudinal data as imple-
mented in VBM8. Individual T1 images were first aligned
first to a T1 template in MNI-space (Montreal Neurolo-
gical Institute) in order to bring them in a common refer-
ence frame with respect to translation and rotation. A
mean image was calculated from these realigned images
and a first realignment of raw data followed enclosing
this mean image as a reference. At this stage individual
images were bias corrected to account for signal inhomo-
geneities. The resulting images were segmented into GM,
white matter (WM) and cerebrospinal fluid (CSF) using a
Maximum-A-Posteriori technique and a partial volume
estimation (PVE) [41].
In order to estimate global tissue volumes we estimated
the sum of local tissue values across the whole brain. Glo-
bal GM volumes across different timepoints were then
tested on significant changes using an analysis of variance
for repeated measurements. In case of a significant effect
of factor ‘time’ global GM volume changes between
Table 2 Magnetic resonance imaging (MRI) parameters of the sequences used in the study
Sequence parameters MPRAGE DWI EPI FLAIR
TR (repetition time, ms) 2,100 3,700 9,000
TE (echo time, ms) 4.8 98 120
TI (inversion time, ms) 1,060 - 2,500
FA (flip angle, °) 15 90 150
NA (no. of acquisitions) 1 2 1
ETL (echo train length) - - 21
Bandwidth (Hz/voxel) 139 1,000 150
Slice thickness (mm) 1 5 5
Orientation Sagittal Transversal Coronal
Matrix (interpolated from) 240 × 256 128 × 128 384 × 384 (187 × 187)
FOV (field of view, mm) 240 × 256 230 × 230 172 × 230
TA (time of acquisition) 8 min 25 s 1 min 4 s 2 min 24 s
Magnetization prepared rapid acquisition gradient echo (MPRAGE), diffusion-weighted echoplanar imaging (DWI EPI) and fluid attenuated inversion recovery
(FLAIR) were used.
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timepoints were tested employing Newman-Keuls post hoc
tests at the nominal level of a of P <0.05. To assess the
stability of measurements among different scanners, total
intracranial volume was measured in addition, computed
as the sum of GM, WM, and total CSF volume. Ideally,
this parameter should remain constant over time thereby
indicating that measurements were not confounded by the
necessary use of different scanners and that no systematic
errors were imported into volume analysis.
Results
At the second timepoint runners had finished 2,475 km
on average, and 4,001 km at timepoint 3. The average
time between the follow-up measurement and the end
of the race was 256 days. Due to constraints imposed by
the demanding running as well as scanning schedules,
not every runner was able to attend every session (see
Tables 1 and 3), and thus the numbers scanned varied.
Biometrical data
As reference we had obtained biometrical data from a
major sample of further 34 runners willing to provide
these data (see Table 1). Comparing the group of ten
participants included into the volumetric study to this
major sample showed that biometrical data did not sig-
nificantly differ, suggesting that the ten-subject group
reflects a representative subsample of the entire runners
group. Also the sample of 7 subjects who had partici-
pated in volumetric follow-up measurements was still
representative for the major sample of 34 runners with
respect to the same biometrical data (see Table 1).
Changes of body weight during and after the TEFR09
The mean body weight of the study subjects decreased
during the run (see Table 4).
For both groups (N = 10 with timepoints 1 to 3 and out
of these N = 7 who also attended follow-up) two different
analyses of variance were computed to test on significant
weight losses over time. For each group there was a sig-
nificant main effect of ‘time’ (ten-subject (10s) group: F
(2,18) = 34.19; P <0.0001; seven-subject (7s) group: F
(3,18) = 28.42; P <0.0001). Post hoc tests in both groups
showed significant weight losses and a regain of weight at
follow-up (see Table 4 and Figure 1).
Changes of global gray matter volumes and total
intracranial volume during and after the TEFR09
The mean global GM volume of the 10s group (see Table 4
and Figure 2) was 671.7 ml (SD 46.1) for timepoint 1, 645.5
ml (38.6) for timepoint 2 and 630.7 ml (49.4) for timepoint
3. The mean global GM volume of the 7s group runners
(with follow-up) was 670.0 ml (SD 38.1) for timepoint 1,
642.9 ml (38.8) at timepoint 2, 630.5 ml (42.6) at timepoint
3 and 671.1 ml (19.5) at timepoint 4 (follow-up). For the
10s group and 7s group (with follow-up), two different ana-
lyses of variance were computed to test on significant glo-
bal GM volume changes over time. Both analyses revealed
a significant main effect of ‘time’ (10s group: F(2,18) =
18.76; P <0.0001; 7s group: F(3,18) = 10.70; P <0.001). For
both the 10s group and the 7s group significant GM
volume losses between timepoints and a regain at follow-
up could be demonstrated (see Table 4 and Figure 2).
Total intracranial volume (TICV), however, showed no
substantial changes over time. Absolute values for time-
points 1 to 3 for the 10s group were: 1,589.0 ml (SD 92.1),
1,586.6 ml (SD 93.7) and 1,584.4 ml (SD 93.1), respec-
tively. At timepoint 4 TICV for the 7s group was 1,592.8
ml (SD 76.8). As for the analysis of GM volume changes,
two different analyses of variance were computed to test
on significant TICV changes over time. There were no
significant effects of ‘time’ in the 10s group with three
timepoints (F(2,18) = 2.29; P = 0.130) or in the 7s group
with four timepoints (F(3,18) = 1.91; P = 0.165).
The TICV difference between timepoints 1 and 2 for
the 10s group was -2.4 ml (SD 6.7), equaling 0.15% of
the total intracranial volume. Between timepoint 1 and
Table 3 Lesion statistics from serial fluid-attenuated inversion recovery (FLAIR) imaging
Comparisons No. of new lesions No. of subjects t Test P value
t1 to t2 -0.08 (0.82) 12 -0.35 0.732
t2 to t3 -0.36 (0.64) 11 -1.90 0.087
t3 to t4 0.17 (0.52) 6 0.79 0.465
Volume change of lesions
t1 to t2 54.9 (247.4) 12 0.77 0.458
t2 to t3 38.3 (116.9) 11 1.09 0.302
t3 to t4 -100.42 (237.7) 6 -1.03 0.348
t1 = timepoint 1, start of the race; t2 = timepoint 2, after an average distance of 2,326 km; t3 = timepoint 3, after an average distance of 4,005 km from t1; t4 =
timepoint 4, follow-up measurements around 8 months after finishing the race. No. of new lesions = across participants averaged number of new lesions (SD)
observed between two consecutive timepoints. No. of subjects = number of subjects with two consecutive FLAIR measurements to enter a paired t test. Volume
change of lesions = for calculation of lesion volumes see Methods section, shown is the difference between averaged sums of lesion volumes obtained at two
consecutive timepoints, units are mm3.
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3 the difference was -4.6 ml (SD 7.4) or 0.29% of TICV. For
the 7s group the difference between timepoint 1 and 4 was
-4.6 ml (6.1) or 0.29%. All differences were non-significant.
Retrospectively, an exploratory analysis of putative white
matter changes was computed in the 7s group with all
four timepoints. An analysis of variance (ANOVA)
revealed a significant effect of ‘time’ (F(3,18) = 4.34; P =
0.018), however it was much smaller than that observed
for GM volume changes in this group (see above). Post
hoc Newman-Keuls tests showed that this effect was
merely due to an increase in WM volume of 3.9% from
timepoint 1 to 3 (P = 0.041) while differences between
timepoints 1 and 2 (P = 0.152) and between 2 and 3 (P =
0.261) were far from significant, as was the difference
between timepoints 1 and 4 (P = 0.554).
Brain lesions
One FLAIR-weighted imaging dataset was lost, so that the
number of subjects in the lesion analysis (last comparison)
is smaller than in the volumetric analysis. With DWI,
no=lesions were seen before, during or after the run (see
Figure 3). With FLAIR imaging, there was a mean of three
lesions visible before the start of the run (see Figure 4).
However, no new lesions appeared during the run (see
Table 3 and Additional file 1, Tables S1-3). Numerically, the
mean number of lesions even seemed to decline during the
run, whereas the volume of the lesions seemed to increase.
However, this is partly due to the high number of lesions in
subject 8, who did not attend follow-up. Observed differ-
ences were statistically not significant according to paired
t tests.
Table 4 Evolution of weight and gray matter (GM) brain volume during the TransEurope-FootRace 2009 (TEFR09)
Parameter Weight in kg, 7s group GM volume in ml, 7s group Weight in kg, 10s group GM volume in ml, 10s group
Timepoint 1, start 75.1 (6.8) 670.0 (38.1) 73.6 (6.6) 671.7 (46.1)
Timepoint 2, 2,400 km 71.2 (6.3)* 642.9 (38.8)** 70.0 (5.8)*** 645.5 (38.6)****
Timepoint 3, 4,005 km 70.5 (6.4)* 630.5 (42.6)** 69.2 (5.9)*** 630.7 (49.4)****
Timepoint 4, follow-up 76.5 (6.2)* 671.1 (19.5)** NA NA
Difference, timepoint 1-2 3.9 (P = 0.0002) 27.1 (P = 0.006) 3.6 (P = 0.0002) 26.2 (P = 0.0013)
Difference, timepoint 1-3 4.6 (P = 0.0002) 39.5 (P = 0.008) 4.4 (P = 0.0002) 40.6 (P = 0.0002)
Difference, timepoint 2-3 0.7 (0.419) 12.4 (P = 0.172) 0.8 (P = 0.159) 14.4 (P = 0.042)
Difference, timepoint 4-3 6.0 (P = 0.0002) 40.6 (P = 0.001) NA NA
Difference, timepoint 4-1 1.4 (P = 0.092) 1.1 (P = 0.898) NA NA
Values are mean (SD).
*P <0.0001 analysis of variance for effect of time with F(3,18) = 28.42; **P <0.001 analysis of variance for effect of time with F(3,18) = 10.70; ***P <0.0001 analysis
of variance for effect of time with F(2,18) = 34.19; ****P <0.0001 analysis of variance for effect of time with F(2,18) = 18.76.
10s group = ten-subject group; 7s group = seven-subject group; NA = not applicable.
Figure 2 Mean global gray matter (GM) volume of the participating group of TransEurope-FootRace 2009 (TEFR09) athletes. Error bars
denote standard deviation; asterisks show statistically significant differences from baseline (timepoint 1).
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There was no statistically significant correlation
between the numbers of lesions observed and biometrical
(weight, height or age) or sports-associated parameters
(training intensity or participation in ultramarathons).
Inter-rater reliability
With diffusion-weighted imaging, there were no lesions
recorded. Therefore, inter-rater reliability could not be cal-
culated. For FLAIR, the numbers of lesions detected by
both raters were nearly identical, so that calculated l was
0.99.
Discussion
The main finding of our study was a global GM volume
decrease during participation in an ultramarathon. This
change was paralleled by a decreasing body weight. Both
changes reversed to the baseline when measured about
8 months after the end of the race. DWI and FLAIR ima-
ging revealed no new brain lesions during the race.
Observed loss in GM volume of about 6% during the 2
months of the race would equal (assuming linearity) an
annual rate of 36%, and therefore appears substantial when
compared with annual rates of volume losses associated
Figure 3 Exemplary slides of the sequences used to detect brain lesions. (A) Axial diffusion-weighted imaging, b1,000. The arrow points to
an older postcontusional brain lesion. (B) Axial apparent diffusion coefficient map. The arrow points to the same lesion as in (A). (C) Coronal
fluid attenuated inversion recovery (FLAIR) image. The arrow points to the same lesion as in (A).
Figure 4 A lesion followed over time. Coronal fluid attenuated inversion recovery (FLAIR) image. The arrow points to a small periventricular
lesion. The lesion shows no difference during the time course. However, the thickness of the subcutaneous fat layer (see red circle) shows a
marked decrease from (A-C) and recovery at (D). (A) Timepoint 1 before the TransEurope-FootRace 2009 (TEFR09) in April 2009; (B) timepoint 2
during the race at 2,326 km; (C) timepoint 3 during the race at 4,005 km; (D) timepoint 4 at follow-up 8 months after the race.
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with natural processes: aging leads to volume reductions of
GM of less than 0.2% annually [18,19], Alzheimer’s disease
shows up to 2% loss per year [20], and multiple sclerosis
leads to annual atrophy rates of about 0.5% [42]. At pre-
sent, we can only speculate about the reasons that may be
responsible for the observed loss in GM volume although
the search for possible factors is constrained by two immi-
nent characteristics: a substantial reduction during ultra-
marathon activity that was reversible upon follow-up.
Therefore, possible factors should be consistent with this
observation, especially reversibility of volume reduction.
Among the various factors causing brain volume
changes [43], some major causes such as intake of alco-
hol or toxic substances can certainly be ruled out. Other
factors such as inflammation and edema, changes in
electrolyte balance, vascular permeability and dehydra-
tion, as well as protein catabolism cannot easily be dis-
carded, and also systemic illnesses and corticosteroids
must be taken into account [44]. For example, brain
volume loss has been shown in illnesses such as kwa-
shiorkor [25], Cushing’s syndrome [45], and anorexia
nervosa [29].
Body fat reduction due to the huge energy deficit
incurred over the course of the race [46] has been shown
in different multistage endurance events [34,35,47].
Besides fat loss, in one report on a multistage ultramara-
thon over 1,200 km a reduction of muscle mass was also
noted [33]. Therefore, catabolism with reduction of fat
and muscle mass has to be expected during a multistage
ultramarathon and may represent a relevant factor for
GM volume loss which is strongly supported by the
apparently parallel loss of body weight (see Figure 4).
Under physiological conditions, the brain controls the
calorie intake to secure a steady supply of necessary nutri-
ents [48]. However, during phases of catabolism protein
loss and hereby reduction of colloidal osmotic pressure
and a shift of fluid to the subarachnoid spaces [43] can
lead to a shrinkage of the whole brain, which may have
contributed to a decrease of GM volume.
Recently it also has been suggested [29] that elevated
cortisol levels might be responsible for GM reduction
in patients with anorexia nervosa. The volume loss was
seemingly reversible with reported recovery [27] after
successful treatment. This has also been shown for
hypercortisolism-induced brain atrophy [45] and for hip-
pocampal atrophy that appeared reversible after hormone
normalization [49]. Interestingly, some recent studies
could show that endurance sports increase cortisol levels
[50,51]. Hence, among those various conditions asso-
ciated with GM volume reduction, hypercortisolism
appears to be a likely candidate given that daily running
with average distances of about 1.7 marathons activates
the hypothalamic-pituitary-adrenal (HPA) axis.
Although dehydration has been shown to relate to a brain
volume reduction of about 0.55%, which was reversible
upon rehydration [52], the extent of these changes does not
explain the changes of about 6% in our present study.
Furthermore, our athletes were extremely well trained and
were sufficiently provided with fluid throughout the entire
race. Regardless, hyponatremia has been shown in mara-
thon runners and has been linked to hypotonic encephalo-
pathy [53] or brain edema [7]. However, hyponatremia
among multistage ultramarathoners is rare according to a
recent report [54], and our analysis of diffusion and
T2-weighted MRI images did not show any new lesions or
signs of edema in our sample. In presence of an excellent
inter-rater reliability we detected only pre-race lesions in
FLAIR imaging, representing older lesions (glial scars),
which are expected to show up on each ensuing examina-
tion. Even though diminishing visibility of edema and glial
scars during a phase of hypercortisolism might seem plausi-
ble, the numerical decrease of the average number of
lesions on FLAIR imaging in our raw data was an artifact
due to varying attendance of subjects (see Table 3 and
Additional file 1, Tables S1-3 for paired t test comparisons).
Therefore no statistically significant variations in the num-
ber of lesions were observed.
This absence of the formation of new brain edema also
supports that hypoxic disruption of the brain barrier [9],
or arterial hypertension (which has been linked to rever-
sible posterior brain edema [10-12] in previous studies)
are rather unlikely to have occurred during the race in
our subjects included. Similarly, disturbances of intravas-
cular coagulation known to happen in marathon runners
[13,14] may produce focal lesions, but no new lesions
were detected during the TEFR09 race.
What really distinguishes participants of TEFR09 from
leisure athletes normally participating in marathon events
is the amount of training they undertake: the TEFR09 par-
ticipants had run a mean of 5,523 km (SD 1,874 km, range
2,500 km to 11,440 km) in the last year with a training
volume of 106.3 km per week (SD 35.3 km/week, range 50
km to 200 km/week) [2]. This reflects a much more exten-
sive training and pre-race running experience compared to
participants of normal (half-) marathon distances (for
example, average weekly workload of 14 km of a cohort in
a previous study on (half-)marathon runners [55]). This
difference in training volume has also been reported by
others [56] who stated that the emphasis during leisure
training is usually more on speed, whereas ultramarath-
oners focus on duration and thus on endurance. Given
their training workload, TEFR09 participants were extre-
mely adapted to the demands of ultramarathon running.
This is also supported by the observation that the partici-
pants’ ultimate goal was completion of the whole multi-
stage race rather than winning single stages. Accordingly,
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a rather low incidence of exercise-associated hyponatremia
in ultramarathoners is reported [33,57] and short term dis-
turbances to the homeostasis of electrolytes or coagulation
that may dominate during short race distances in less
trained leisure athletes are rather unlikely to have contrib-
uted to the present results.
Given our above-mentioned criteria of substantiality
and reversibility of present GM volume reductions only a
subset of the discussed factors seem more likely than
others to have contributed to present results. The loss of
proteins as a likely relevant factor is further supported by
the apparently strong common variation of body weight
and GM volume which both returned to the baseline
after 8 months. Furthermore, it is not unlikely that the
return to baseline also aligned with hypercortisolism and
possibly hyponatremia.
Therefore, further research is needed to find out each
factor’s contribution and their possible interaction lead-
ing to substantial and reversible GM volume loss during
very long distance running.
Strengths and limits
The main strength of this study was its unique setting
with a naturalistic and continuous observation of ultra-
endurance athletes reaching the limits of physical endur-
ance. However, this setup entailed its own limitation
since the number of participating athletes was small and
attendance varied. Nevertheless, this is the first study to
report brain volume changes or possible brain lesions of
multistage ultramarathon runners observed during the
race with a mobile MRI scanner. Since this truck-
mounted scanner was available only for the run, scan-
ning before the race and on follow-up had to be per-
formed on different scanners although these MRI
scanners were identical models and used identical
sequence parameters. Due to the scanning on different
scanners this report is limited to the exploration of glo-
bal brain volumes, which are thought to be much less
sensitive to the problem of using different MRI scanners
than voxel based morphometric analyses of regional
volume differences. Furthermore, a calculation of total
intracranial volume has shown that measurements were
nearly identical across the different scanners. Variations
of intracranial volumes were statistically insignificant
and with 0.3% of the total more than a magnitude less
than observed gray matter volume changes of 6%. Also,
the results are deemed plausible, since the measure-
ments during the race were performed on the same
mobile scanner and the volume decrease continues from
timepoint 1 over 2 to 3. This is expected because of the
protracted metabolic load during the run. Systematic
errors due to the change of the scanner between time-
point 1 and 2 would affect only the first comparison.
Therefore, present results on GM volumes changes over
time are thought to be robust, although they had to be
acquired on different scanners.
Conclusions
Whereas focal brain lesions and edema have been fre-
quently reported in symptomatic athletes after single
marathon runs, in the present study on prospectively
observed participants of the multistage ultramarathon
TEFR09, no new lesions were detected by serial MRI. It
is thought that in well trained individuals, no short-term
noxious brain events occur even after repeated loading in
a multistage ultramarathon. However, reversible brain
volume reduction during an ultramarathon could be
shown. Possible mechanisms might be loss of proteins or
hypercortisolism. On a larger scale, extreme running may
serve as a model to better understand those mechanisms
involved in transient brain volume reductions.
Further studies must not only address the exact
mechanisms but also the behavioral consequences of these
changes. It is possible that these findings might then be
useful for the understanding of diseases characterized by
(transient) brain volume changes.
Additional material
Additional file 1: Tables S1-3. Table S1: Fluid-attenuated inversion
recovery (FLAIR) imaging of brain lesions. Observations from timepoint 1
(t1) to t2; only subjects with two consecutive measurements. The table
contains single subject data for FLAIR lesion comparisons between
timepoints 1 to 2. Table S2: FLAIR imaging of brain lesions. Observations
from t2 to t3; only subjects with two consecutive measurements. The
table contains single subject data for FLAIR lesion comparisons between
timepoints 2 to 3. Table S3: FLAIR imaging of brain lesions. Observations
from t3 to t4; only subjects with two consecutive measurements. The
table contains single subject data for FLAIR lesion comparisons between
timepoints 3 to 4.
Abbreviations
DWI EPI: diffusion-weighted echoplanar imaging; FLAIR: fluid-attenuated
inversion recovery; GM: gray matter; MRI: magnetic resonance imaging;
TEFR09: TransEurope-FootRace 2009; TICV: total intracranial volume; WM:
white matter.
Authors’ contributions
WF proposed and designed the study, read the images, worked on the
statistical analysis and wrote the report. SF planned the statistical analysis of
the volumetric data and performed it, and wrote parts of the report. FB
helped to conceive and plan the study and wrote parts of the paper. CG
revised the methodology of the statistical analysis and wrote parts of the
paper. APW planned the study and the physical properties of the used
sequences and wrote part of the manuscript. MM took part in the statistical
analysis and revised the paper. MSJ participated in statistical analysis and
wrote parts of the manuscript. BLS planned the study and wrote parts of the
manuscript. CB planned the study and sampled data. GG contributed to the
statistical analyses of the brain and non-brain data and wrote parts of the
report. UHS planned the TEFR09 project and this study and sampled data
and read the images. All authors critically revised and approved the final
manuscript.
Freund et al. BMC Medicine 2012, 10:170
http://www.biomedcentral.com/1741-7015/10/170
Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This project was mainly supported by the German Research Association
(DFG: ‘Deutsche Forschungsgemeinschaft’), under grants SCHU 2514/1-1 and
SCHU 2514/1-2. Other non-public funds were received from Siemens
medical and the Medical Faculty of the University of Ulm. All funding was
unrestricted. None of the funding bodies had any role in the study design,
data collection, data analysis, data interpretation, manuscript preparation or
decision to publish. Heike Wiedelbach and Martin Erhard participated in data
acquisition.
Author details
1Department of Diagnostic and Interventional Radiology, University Hospitals
Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany. 2Department of
Neurology, University Medical Centre Mainz, Langenbeckstraße 1/503, 55131
Mainz, Germany. 3Departments of Psychiatry and Neurology, Jena University
Hospital, Jahnstraße 3, 07743 Jena, Germany. 4Section Neuropsychology and
Functional Imaging, University Hospitals Ulm, Leimgrubenweg 12-14, 89073
Ulm, Germany. 5Section Neuroradiology, University Hospitals Ulm, Albert-
Einstein-Allee 23, 89081 Ulm, Germany. 6Outpatient Rehabilitation Centre at
University Hospitals Ulm, Pfarrer-Weiß-Weg 10, 89077 Ulm, Germany.
Received: 19 June 2012 Accepted: 21 December 2012
Published: 21 December 2012
References
1. Schulze I: TransEurope-FootRace 2009. Bari-Nordkap - 4.487,7 km in
64 Tagesetappen Leipzig, Germany: Engelsdorfer Verlag; 2010.
2. Schuetz UH, Schmidt-Trucksäss A, Knechtle B, Machann J, Wiedelbach H,
Erhardt M, Freund W, Gröninger S, Brunner H, Schulze I, Brambs HJ,
Billich C: The Transeurope Footrace Project: longitudinal data acquisition
in a cluster randomized mobile MRI observational cohort study on 44
endurance runners at a 64-stage 4,486km transcontinental
ultramarathon. BMC Med 2012, 10:78.
3. Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA,
Duncan CN, Olson DP, Salerno AE, Newburger JW, Greenes DS:
Hyponatremia among runners in the Boston Marathon. N Engl J Med
2005, 352:1550-1556.
4. Levine BD, Thompson PD: Marathon maladies. N Engl J Med 2005,
352:1516-1518.
5. Noakes TD, Sharwood K, Speedy D, Hew T, Reid S, Dugas J, Almond C,
Wharam P, Weschler L: Three independent biological mechanisms cause
exercise-associated hyponatremia: evidence from 2,135 weighed
competitive athletic performances. Proc Natl Acad Sci USA 2005,
102:18550-18555.
6. Kashyap AS, Anand KP, Kashyap S: Sudden collapse of a young female
cross country runner. Br J Sports Med 2006, 40:e11.
7. Ayus JC, Varon J, Arieff AI: Hyponatremia, cerebral edema, and
noncardiogenic pulmonary edema in marathon runners. Ann Intern Med
2000, 132:711-714.
8. Ayus JC: Sodium and potassium disorders. In Textbook of critical care.
Edited by: Shoemaker WC. Philadelphia, PA: WB Saunders; 2000:853-861.
9. Bailey DM, Bartsch P, Knauth M, Baumgartner RW: Emerging concepts in
acute mountain sickness and high-altitude cerebral edema: from the
molecular to the morphological. Cell Mol Life Sci 2009, 66:3583-3594.
10. Decker DA, Falchook AD, Yachnis AT, Waters MF: Radiographic and
pathologic findings in an atypical brainstem variant of reversible
posterior leukoencephalopathy syndrome. Neurologist 2009, 15:364-366.
11. Bartynski WS: Posterior reversible encephalopathy syndrome, part 1:
fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008,
29:1036-1042.
12. Bartynski WS: Posterior reversible encephalopathy syndrome, part 2:
controversies surrounding pathophysiology of vasogenic edema. AJNR
Am J Neuroradiol 2008, 29:1043-1049.
13. Scobie BA: Gastrointestinal emergencies with marathon-type running:
omental infarction with pancreatitis and liver failure with portal vein
thrombosis. N Z Med J 1998, 111:211-212.
14. Holman ND, Schneider AJ: Multi-organ damage in exertional heat stroke.
Neth J Med 1989, 35:38-43.
15. Slavich G, Poser S, Antonutto G, Fregolent R, Piccoli G, Enrico di
Prampero P: Prolonged nocturnal asystole and cerebral neurogliosis in a
marathon runner. J Cardiovasc Med 2011, 12:901-903.
16. Pantoni L: Leukoaraiosis: from an ancient term to an actual marker of
poor prognosis. Stroke 2008, 39:1401-1403.
17. van Straaten EC, Fazekas F, Rostrup E, Scheltens P, Schmidt R, Pantoni L,
Inzitari D, Waldemar G, Erkinjuntti T, Mantyla R, Wahlund LO, Barkhof F:
Impact of white matter hyperintensities scoring method on correlations
with clinical data: the LADIS study. Stroke 2006, 37:836-840.
18. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS:
A voxel-based morphometric study of ageing in 465 normal adult
human brains. Neuroimage 2001, 14:21-36.
19. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Markesbery WR: Age and
gender effects on human brain anatomy: a voxel-based morphometric
study in healthy elderly. Neurobiol Aging 2007, 28:1075-1087.
20. O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, Gholkar A,
Crum WR, Rossor MN, Fox NC: Progressive brain atrophy on serial MRI in
dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001,
56:1386-1388.
21. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN: Imaging
of onset and progression of Alzheimer’s disease with voxel-compression
mapping of serial magnetic resonance images. Lancet 2001, 358:201-205.
22. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L: Use of the brain
parenchymal fraction to measure whole brain atrophy in relapsing-
remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology
1999, 53:1698-1704.
23. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R,
Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D,
Frost C, Langbehn DR, Reilmann R, Stout JC: Biological and clinical
changes in premanifest and early stage Huntington’s disease in the
TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011,
10:31-42.
24. Katzman DK, Lambe EK, Mikulis DJ, Ridgley JN, Goldbloom DS, Zipursky RB:
Cerebral gray matter and white matter volume deficits in adolescent
girls with anorexia nervosa. J Pediatr 1996, 129:794-803.
25. Gunston GD, Burkimsher D, Malan H, Sive AA: Reversible cerebral
shrinkage in kwashiorkor: an MRI study. Arch Dis Child 1992, 67:1030-1032.
26. Geibprasert S, Gallucci M, Krings T: Alcohol-induced changes in the brain
as assessed by MRI and CT. Eur Radiol 2010, 20:1492-1501.
27. Swayze VW, Andersen AE, Andreasen NC, Arndt S, Sato Y, Ziebell S: Brain
tissue volume segmentation in patients with anorexia nervosa before
and after weight normalization. Int J Eat Disord 2003, 33:33-44.
28. Golden NH, Ashtari M, Kohn MR, Patel M, Jacobson MS, Fletcher A,
Shenker IR: Reversibility of cerebral ventricular enlargement in anorexia
nervosa, demonstrated by quantitative magnetic resonance imaging.
J Pediatr 1996, 128:296-301.
29. Castro-Fornieles J, Bargallo N, Lazaro L, Andres S, Falcon C, Plana MT,
Junque C: A cross-sectional and follow-up voxel-based morphometric
MRI study in adolescent anorexia nervosa. J Psychiatr Res 2009,
43:331-340.
30. Knudsen L, Drummond PD: Cold-induced limb pain decreases sensitivity
to pressure-pain sensations in the ipsilateral forehead. Eur J Pain 2009,
13:1023-1029.
31. Van den Eynde F, Treasure J: Neuroimaging in eating disorders and
obesity: implications for research. Child Adolesc Psychiatr Clin N Am 2009,
18:95-115.
32. Reimers CD, Knapp G, Tettenborn B: Impact of Physical Activity on
Cognition. Can Physical Activity Prevent Dementia? Aktuelle Neurologie
2012, 39:276-291.
33. Knechtle B, Duff B, Schulze I, Kohler G: A multi-stage ultra-endurance run
over 1,200 km leads to a continuous accumulation of total body water.
J Sports Sci Med 2008, 7:356-364.
34. Knechtle B, Knechtle P, Schuck R, Andonie JL, Kohler G: Effects of a Deca
Iron Triathlon on body composition: a case study. Int J Sports Med 2008,
29:343-351.
35. Knechtle B, Salas Fraire O, Andonie JL, Kohler G: Effect of a multistage
ultra-endurance triathlon on body composition: World Challenge Deca
Iron Triathlon 2006. Br J Sports Med 2008, 42:121-125.
36. Bland JM, Altman DG: Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986,
1:307-310.
Freund et al. BMC Medicine 2012, 10:170
http://www.biomedcentral.com/1741-7015/10/170
Page 10 of 11
37. Jepsen JR, Laursen LH, Hagert CG, Kreiner S, Larsen AI: Diagnostic accuracy
of the neurological upper limb examination I: inter-rater reproducibility
of selected findings and patterns. BMC Neurol 2006, 6:8.
38. Portney LG, Watkins MP: Correlations. In Foundations of Clinical Research:
Applications to Practice. Volume 23. Upper Saddle River, NJ: Prentice Hall
Health; 2000:491-508.
39. FIL Methods Group: SPM 8. [http://www.fil.ion.ucl.ac.uk/spm/software/spm8/].
40. Structural Brain Mapping Group: VBM8 Toolbox. [http://dbm.neuro.uni-jena.
de/vbm/download/].
41. Tohka J, Zijdenbos A, Evans A: Fast and robust parameter estimation for
statistical partial volume models in brain MRI. Neuroimage 2004, 23:84-97.
42. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P,
Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D:
Long-term subcutaneous interferon beta-1a therapy in patients with
relapsing-remitting MS. Neurology 2006, 67:944-953.
43. Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H,
Racke MK, Dwyer MG, Frohman EM, Khan O: Mechanisms of action of
disease-modifying agents and brain volume changes in multiple
sclerosis. Neurology 2008, 71:136-144.
44. Jagust WJ, Noseworthy JH: Brain atrophy as a surrogate marker in MS:
faster, simpler, better? Neurology 2000, 54:782-783.
45. Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, Lesage J,
Lafontaine L, Lacroix A: Loss of brain volume in endogenous Cushing’s
syndrome and its reversibility after correction of hypercortisolism.
J Clin Endocrinol Metabol 2002, 87:1949-1954.
46. Enqvist JK, Mattsson CM, Johansson PH, Brink-Elfegoun T, Bakkman L,
Ekblom BT: Energy turnover during 24 hours and 6 days of adventure
racing. J Sports Sci 2010, 28:947-955.
47. Herbst L, Knechtle B, Lopez CL, Andonie JL, Fraire OS, Kohler G, Rust CA,
Rosemann T: Pacing strategy and change in body composition during a
deca iron triathlon. Chinese J Physiol 2011, 54:255-263.
48. Peters A, Schweiger U, Pellerin L, Hubold C, Oltmanns KM, Conrad M,
Schultes B, Born J, Fehm HL: The selfish brain: competition for energy
resources. Neurosci Biobehav Rev 2004, 28:143-180.
49. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE:
Decrease in cortisol reverses human hippocampal atrophy following
treatment of Cushing’s disease. Biol Psychiatry 1999, 46:1595-1602.
50. Hew-Butler T, Noakes TD, Soldin SJ, Verbalis JG: Acute changes in
endocrine and fluid balance markers during high-intensity, steady-state,
and prolonged endurance running: unexpected increases in oxytocin
and brain natriuretic peptide during exercise. Eur J Endocrinol 2008,
159:729-737.
51. Kraemer WJ, Fragala MS, Watson G, Volek JS, Rubin MR, French DN,
Maresh CM, Vingren JL, Hatfield DL, Spiering BA, Yu-Ho J, Hughes SL,
Case HS, Stuempfle KJ, Lehmann DR, Bailey S, Evans DS: Hormonal
responses to a 160-km race across frozen Alaska. Br J Sports Med 2008,
42:116-120, discussion 120.
52. Duning T, Kloska S, Steinstrater O, Kugel H, Heindel W, Knecht S:
Dehydration confounds the assessment of brain atrophy. Neurology 2005,
64:548-550.
53. Siegel AJ, Verbalis JG, Clement S, Mendelson JH, Mello NK, Adner M,
Shirey T, Glowacki J, Lee-Lewandrowski E, Lewandrowski KB: Hyponatremia
in marathon runners due to inappropriate arginine vasopressin
secretion. Am J Med 2007, 120:461 e411-467.
54. Knechtle B, Knechtle P, Rust CA, Gnadinger M, Imoberdorf R, Kohler G,
Rosemann T, Ballmer P: Regulation of electrolyte and fluid metabolism in
multi-stage ultra-marathoners. Horm Metab Res 2012, 44:919-926.
55. Freund W, Billich C, Brambs HJ, Weber F, Schuetz UH: MRI changes of
achilles tendon and hindfoot in experienced runners and beginners
during training and after a (half)-marathon competition [in German].
Zeitschrift fur Orthopadie und Unfallchirurgie 2011, 149:407-417.
56. Rüst CA, Knechtle B, Knechtle P, Rosemann T: Similarities and differences
in anthropometry and training between recreational male 100-km ultra-
marathoners and marathoners. J Sports Sci 2012, 30:1249-1257.
57. Knechtle B, Knechtle P, Rosemann T: Low prevalence of exercise-
associated hyponatremia in male 100 km ultra-marathon runners in
Switzerland. Eur J Appl Physiol 2011, 111:1007-1016.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/10/170/prepub
doi:10.1186/1741-7015-10-170
Cite this article as: Freund et al.: Substantial and reversible brain gray
matter reduction but no acute brain lesions in ultramarathon runners:
experience from the TransEurope-FootRace Project. BMC Medicine 2012
10:170.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Freund et al. BMC Medicine 2012, 10:170
http://www.biomedcentral.com/1741-7015/10/170
Page 11 of 11
